ropinirole and Dyskinesia, Medication-Induced studies

Research Excerpts

Excerpt	Relevance	Reference
"Data from the ropinirole versus levodopa studies 056 and REAL-PET in early Parkinson's disease were pooled and manipulated to calculate levodopa dose per kilogram body weight."	7.74	Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. ( Brooks, D; Rascol, O; Ross, IN; Sharma, JC, 2008)
"Data from the ropinirole versus levodopa studies 056 and REAL-PET in early Parkinson's disease were pooled and manipulated to calculate levodopa dose per kilogram body weight."	3.74	Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. ( Brooks, D; Rascol, O; Ross, IN; Sharma, JC, 2008)
"Ropinirole was found to be safe and well-tolerated."	2.71	Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. ( Cho, IS; Ha, JH; Im, JH; Lee, MC, 2003)
" In the group of patients with prior dopamine-agonist therapy, more patients reported adverse events in the ropinirole group (90% versus 79%, p < 0."	2.70	A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. ( Brooks, DJ; Brunt, ER; Korczyn, AD; Montastruc, JL; Stocchi, F, 2002)
"Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary."	2.69	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. ( Brooks, DJ; Clarke, CE; De Deyn, PP; Korczyn, AD; Lang, AE; Rascol, O, 2000)
"This review describes the pharmacologic and pharmacokinetic properties of selected DAs and relates these characteristics to clinical outcomes, with an emphasis on adverse events."	2.43	A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. ( Burger, E; Härtter, S; Kvernmo, T, 2006)
"Ropinirole treatment was continued but some animals also received l-dopa BID or four times daily (QID) with and without entacapone or vehicle for a further 16 days."	1.34	The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. ( Jackson, MJ; Jenner, P; Olanow, W; Rose, S; Smith, LA; Stockwell, KA; Tayarani-Binazir, K; Zubair, M, 2007)

Research

Studies (36)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Adverse Events

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.78)	18.2507
2000's	25 (69.44)	29.6817
2010's	9 (25.00)	24.3611
2020's	1 (2.78)	2.80

Authors	Studies
Elabi, OF	1
Espa, E	1
Skovgård, K	1
Fanni, S	1
Cenci, MA	2
Shin, E	2
Lisci, C	1
Tronci, E	1
Fidalgo, C	1
Stancampiano, R	1
Björklund, A	2
Carta, M	3
van Boven, JF	1
Novak, A	1
Driessen, MT	1
Boersma, C	1
Boomsma, MM	1
Postma, MJ	1
Shiga, Y	1
Kanaya, Y	1
Kono, R	1
Takeshima, S	1
Shimoe, Y	1
Kuriyama, M	1
Montgomery, EB	1
Lyons, KE	2
Pahwa, R	2
Onofrj, M	1
Bonanni, L	1
De Angelis, MV	1
Anzellotti, F	1
Ciccocioppo, F	1
Thomas, A	1
Lane, EL	1
Dunnett, SB	1
Carta, AR	2
Frau, L	2
Pinna, A	2
Morelli, M	2
Watts, RL	1
Sethi, K	1
Stern, M	1
Hauser, RA	1
Olanow, W	2
Gray, AM	1
Adams, B	1
Earl, NL	1
Fisone, G	2
Garcia, J	1
Winkler, C	1
Batla, A	1
Stamelou, M	1
Mencacci, N	1
Schapira, AH	1
Bhatia, KP	1
Tel, BC	1
Zeng, BY	1
Cannizzaro, C	1
Pearce, RK	3
Rose, S	4
Jenner, P	6
Im, JH	1
Ha, JH	1
Cho, IS	1
Lee, MC	1
Ravenscroft, P	1
Chalon, S	1
Brotchie, JM	1
Crossman, AR	1
Kurlan, R	1
Lundblad, M	1
Usiello, A	1
Håkansson, K	1
Rascol, O	3
Brooks, DJ	3
Korczyn, AD	3
De Deyn, PP	2
Clarke, CE	2
Lang, AE	2
Abdalla, M	1
Kvernmo, T	1
Härtter, S	1
Burger, E	1
Jackson, MJ	4
Smith, LA	2
Al-Barghouthy, G	1
Zubair, M	1
Tayarani-Binazir, K	1
Stockwell, KA	2
Virley, DJ	1
Perren, M	1
Iravani, MM	1
Sharma, JC	1
Ross, IN	1
Brooks, D	1
Lucia, F	1
Annalisa, P	1
Pontis, S	1
Silvia, P	1
Simola, N	1
Nicola, S	1
Schintu, N	1
Nicoletta, S	1
Micaela, M	1
Banerji, T	1
Marsden, CD	1
Hiner, BC	1
Earnhart, M	1
Frucht, S	1
Yamamoto, T	1
Weiner, WJ	1
Factor, SA	1
Reichmann, H	1
Lachenmayer, L	1
Maratos, EC	1
Mazzoni, P	1
Brunt, ER	1
Montastruc, JL	1
Stocchi, F	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease[NCT00986245]	Phase 4	82 participants (Actual)	Interventional	2009-09-30	Completed
A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease[NCT04295642]	Phase 1	24 participants (Actual)	Interventional	2020-01-08	Completed
A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist[NCT01338662]		500 participants (Anticipated)	Observational	2011-05-31	Recruiting
Determining the Natural History of Levodopa-Induced Dyskinesia (LID)[NCT01003002]		0 participants (Actual)	Observational	2010-12-31	Withdrawn (stopped due to Funding not secured.)
Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids[NCT01563913]	Phase 1	33 participants (Actual)	Interventional	2012-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Patients who have adverse events (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Compliance

Intervention	participants (Number)
Once-daily of Ropinirole PR	33
Twice-daily of Ropinirole PR	28

Compliances after 8 weeks in each arm or at last visit for early completion. Compliance was calcuated by the percentage of used medication. (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Early Morning Off Symptoms

Intervention	percentage of used medication (Mean)
Once-daily of Ropinirole PR	98.4
Twice-daily of Ropinirole PR	97.6

"Sleep questionnaire 3 for early morning off symptoms Visual analogue scale: 0~10 Higher values represent worse early morning off symptoms." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Epworth Sleep Scale

Intervention	units on a scale (Mean)
Once-daily of Ropinirole PR	2.5
Twice-daily of Ropinirole PR	2.9

"Epworth sleep scale after 8 weeks in each arm or at last visit for early completion.~Range: 0~24 Higher values represent worse daytime-sleepiness." (NCT00986245)
Timeframe: 8 weeks in each arm or at last visit for early completion

Hoehn and Yahr Stage

Intervention	units on a scale (Mean)
Once-daily of Ropinirole PR	6.3
Twice-daily of Ropinirole PR	6.4

Hoehn and Yahr(HY) stage for parkinsonism after 8 weeks in each arm or at last visit for early completion Range: 0~5 Higher values represent more severe parkinsonism (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Nocturnal Off-symptoms

Intervention	Scores on a scale (Mean)
Once-daily of Ropinirole PR	2.1
Twice-daily of Ropinirole PR	2.1

"Sleep questionnaire 2 for Nocturnal off-symptoms Visual analogue scale: 0~10 Higher values represent worse nocturnal off-symptoms." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Overall Quality of Sleep

Intervention	units on a scale (Mean)
Once-daily of Ropinirole PR	2.9
Twice-daily of Ropinirole PR	3.1

"Sleep questionnaire 1 for Overall quality of sleep Visual analogue scale: 0~10 Higher values represent worse overall sleep quality." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Patient Preference

Intervention	units on a scale (Mean)
Once-daily of Ropinirole PR	2.9
Twice-daily of Ropinirole PR	3.2

Patient preference between once-daily and twice-daily regimen (NCT00986245)
Timeframe: After 16 weeks or at last visit for early completion

Patients Who Have Global Impression for Improvement

Intervention	participants (Number)
Once-daily	17
Twice-daily	31
No Preference	13

Patients who have global impression for improvement for each dosing. (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Patients Who Have Global Impression for Improvement to Duration of Dyskinesia

Intervention	participants (Number)
Once-daily of Ropinirole PR	32
Twice-daily of Ropinirole PR	42

Patients who have global impression for improvement to duration of dyskinesia compared (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Patients Who Have Global Impression for Improvement to Duration of Motor Fluctuation

Intervention	participants (Number)
Once-daily of Ropinirole PR	13
Twice-daily of Ropinirole PR	16

Patients who have global impression for improvement to duration of motor fluctuation (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Patients Who Have Global Impression for Improvement to Severity of Dyskinesia

Intervention	participants (Number)
Once-daily of Ropinirole PR	27
Twice-daily of Ropinirole PR	38

Patients who have Global Impression for Improvement to Severity of Dyskinesia compared (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Patients Who Have Global Impression for Improvement to Severity of Motor Fluctuation

Intervention	participants (Number)
Once-daily of Ropinirole PR	16
Twice-daily of Ropinirole PR	15

Patients who have global impression for improvement to severity of motor fluctuation compared (NCT00986245)
Timeframe: After 8 weeks in each arm or at last visit for early completion

Unified Parkinson's Disease Rating Scale, Part 3

Intervention	participants (Number)
Once-daily of Ropinirole PR	28
Twice-daily of Ropinirole PR	34

"Unified Parkinson's disease rating scale (UPDRS) motor scale after 8 weeks in each arm or at last visit for early completion.~UPDRS part 3 is motor scale for parkinson's disease. Range: 0~108 Higher values represent more severe motor symptoms of parkinsonism." (NCT00986245)
Timeframe: 8 weeks for each arm or at last visit

Efficacy of DHA - Change in Blood ng/dL Levels

Intervention	units on a scale (Mean)
Once-daily of Ropinirole PR	17.5
Twice-daily of Ropinirole PR	17.1

Therapeutic level monitoring will be accomplished by analyzing blood levels for DHA. (NCT01563913)
Timeframe: baseline and 1.5 years

Efficacy of DHA - Number of Participants With An Abnormal Safety Lab (CBC)

Intervention	ng/dL - Blood (Mean)
Docosahexaenoic Acid	102.18
Placebo:	-13.20

This study is seeking to determine the safety/efficacy of DHA in Parkinson's disease patients. The safety/efficacy of DHA will be determined using periodic safety lab information. Safety labs for complete blood count (CBC) were performed at each inpatient visit, reviewed by the PI, and marked as normal or abnormal. (NCT01563913)
Timeframe: Year 1

Article	Year
Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia. Cells, 2023, 07-14, Volume: 12, Issue:14 Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Micr	2023
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation. Neurobiology of disease, 2014, Volume: 62 Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease	2014
Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands. Drugs & aging, 2014, Volume: 31, Issue:3 Topics: Antiparkinson Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Dyskinesia, Drug-Induced;	2014
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report. Rinsho shinkeigaku = Clinical neurology, 2016, 06-22, Volume: 56, Issue:6 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bites and Stings; Drug Interactions; Drug Ther	2016
Agonist or levodopa for Parkinson disease? Ultimately, it doesn't matter; neither is good enough. Neurology, 2009, Jun-16, Volume: 72, Issue:24 Topics: Bromocriptine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Follow-Up Studies; Huma	2009
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behavioural brain research, 2010, Nov-12, Volume: 213, Issue:1 Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-I	2010
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Experimental neurology, 2010, Volume: 224, Issue:2 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni	2010
Monitoring dyskinesia with Zif. Experimental neurology, 2010, Volume: 226, Issue:1 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Biomarker	2010
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiology of disease, 2012, Volume: 47, Issue:3 Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso	2012
Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:8 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Indoles; Middle Aged; Parkinson Dise	2013
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience, 2002, Volume: 115, Issue:4 Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Dr	2002
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Experimental neurology, 2004, Volume: 185, Issue:1 Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine A	2004
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology, 2005, Mar-08, Volume: 64, Issue:5 Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug	2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental neurology, 2005, Volume: 194, Issue:1 Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal	2005
Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental neurology, 2007, Volume: 204, Issue:1 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Dopamine Agents; Dopamine Agonist	2007
The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Experimental neurology, 2007, Volume: 208, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Catechols;	2007
Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Experimental neurology, 2008, Volume: 211, Issue:1 Topics: Administration, Oral; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Drug Administrati	2008
Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. European journal of neurology, 2008, Volume: 15, Issue:5 Topics: Age Factors; Aged; Antiparkinson Agents; Body Size; Body Weight; Dyskinesia, Drug-Induced; Female; H	2008
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (New York, N.Y.), 2008, Volume: 62, Issue:7 Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St	2008
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithr	1998
Treatments for Parkinson's disease. Health news (Waltham, Mass.), 2000, Volume: 6, Issue:6 Topics: Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa	2000
Ropinirole as compared with levodopa in Parkinson's disease. The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced;	2000
Ropinirole as compared with levodopa in Parkinson's disease. The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Sleep	2000
Ropinirole as compared with levodopa in Parkinson's disease. The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Hallucinations; Humans; Indoles; Levodopa; Parkinson	2000
Ropinirole as compared with levodopa in Parkinson's disease. The New England journal of medicine, 2000, Sep-21, Volume: 343, Issue:12 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Indoles; Levodopa; Parkinson Disease; Qualit	2000
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus). Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:4 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Respon	2001
Literature alert. Current neurology and neuroscience reports, 2001, Volume: 1, Issue:4 Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Fetal Tissue Transplantation; Humans; Incidence; Ind	2001

ropinirole and Dyskinesia, Medication-Induced